Crossmark

The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern

Crossref DOI link: https://doi.org/10.1007/s00296-018-4097-y

Published Online: 2018-06-29

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cea-Calvo, Luis

Raya, Enrique

Marras, Carlos

Salman-Monte, Tarek C.

Ortiz, Ana

Salvador, Georgina

Monteagudo, Indalecio

Carmona, Loreto

Fernandez, Sabela

Arteaga, Maria J.

Calvo-Allén, Jaime
Funding

Funding for this research was provided by:

Merck Sharp & Dohme Spain
License Information

Text and Data Mining valid from 2018-06-29
More Information

Article History

Received: 25 May 2018

Accepted: 27 June 2018

First Online: 29 June 2018

Change Date: 25 July 2018

Change Type: Correction

Change Details: In the original publication, the family name of the last author was incorrect. The correct name should read as Jaime Calvo-Alén.

Compliance with ethical standards

:

: María J. Arteaga, Sabela Fernández and Luis Cea-Calvo are full-time employees of Merck Sharp & Dohme (MSD) Spain. The other co-authors of the manuscript were also study investigators, and they or their institution received financial compensation for the enrolment of patients in the study. Georgina Salvador has received payments for lectures or educational presentations from BMS, Roche, AbbVie, Amgen, Pfizer and MSD. Ana Ortiz has received payments for consultancy from Lilly and Janssen, for educational presentations from UCB, Roche, AbbVie, Lilly and Pfizer, and meeting expenses from UCB, AbbVie, Novartis and Janssen. The remaining authors declare no conflict of interest.